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Summary 
The frequencies of 13 different Ha-ras proto-oncogene alleles have been estimated in 92 breast cancer 
patients and 60 unaffected individuals. The Ha-ras alleles can be identified using a DNA restriction fragment 
length polymorphism (RFLP) closely linked to the 3' end of the gene, and are characterized by a different 
length due to a region of sequences repeated a variable number of times (variable tandem repeats, VTR). 
The statistica] analysis of the data obtained shows that the frequency of alleles ranging between specific 
length limits is significantly higher in breast cancer patients than in controls. The same applies to specific 
genotypes bearing the aforementioned alleles. This suggests that the inheritance of these alleles may be 
associated with an increased risk of developing breast cancer. 
Introduction 
Ha-ras is a proto-oncogene whose activation has 
been estimated to occur in about 10 to 15% of 
primary solid tumors [I.]. Coding sequence muta- 
tions, causing amino acid substitutions at critical 
positions within the p21 product, as well as trunca- 
tion of a putative 5' exon, have been reported to 
represent critical steps in the Ha-ras activation pro- 
cess [2-6]. Recent microinjection experiments 
have also demonstrated that overdosage of the nor- 
mal Ha-ras product may be sufficient to induce cell 
transformation [7] and, with respect to norma1 tis- 
sues, increased amounts of p21 have been found in 
tumor cells of primary breast carcinomas and have 
been shown to correlate with other clinica1 and 
prognostic variables [8, 91. 
These circumstances, and others as well, greatly 
support the hypothesis of an involvement of the 
Ha-ras proto-oncogene in tumorigenesis, although 
its precise role in this process still remains to be 
defined [lo]. 
The Ha-ras gene is characterized by the presence 
of a closely linked restriction fragment length poly- 
morphism (RFLP), due to the presence of a 28 
nucleotide sequence that can be repeated a var- 
iable number of times [11~]. This variable tandem 
repeat (VTR) region is located about 1 kb down- 
stream from the 3' end of the gene (Fig. 1). Using a 
probe for this region, severa1 allelic fragments of 
different size, which define a corresponding num- 
ber of Ha-ras alleles, can be identified by Southern 
blotting analysis. 
Studies investigating whether the presence of 
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human Ha-ras 
Fig. I. Restriction map of the human Ha-ras proto-oncogene; B = Bam HI, S = Sst I, Bs = Bst EII, A = Ava 11, M = Msp I, C = Cla I. 
'i'he black boxes represent exons, the open box the VTR region. Only the Ava I1 and Msp I sites (marked by asterisks) irnmediately 
flanking the VTR region have been included in the map. 
some Ha-ras alleles may be associated with an in- 
creased risk of developing cancer have reached 
controversia1 results. Whereas different frequen- 
cies of specific Ha-ras alleles were initially reported 
in neoplastic and normal DNAs of cancer patients 
compared to normal subjects [12], subsequent 
studies performed on patients affected by specific 
tumors failed to find significant associations [13, 
141. Recently , however, Lidereau et al. [15], study- 
ing a large series of tumor and peripheral blood 
DNA samples obtained from breast cancer pa- 
tients, observed a high frequency of rare Ha-ras 
alleles compared to a contro1 population. As this 
observation, if confirmed, would have major impli- 
cations for assessing the individua1 risk to breast 
cancer susceptibility, we found it interesting to ana- 
lyze the Ha-ras polymorphism distribution be- 
tween breast cancer patients and controls in an- 
other ethnic group. Moreover, as modifications of 
some polymorphisms present on the short arm of 
chromosome 11 have been reported to occur fre- 
quently in breast cancer tumor tissue (27% of the 
cases) [l61 as well as in other tumors compared to 
the germ-line pattern visible in the peripheral 
blood DNA, we have performed our study exclu- 
sively on leucocyte DNA samples. 
Materials and methods 
Peripheral blood samples of 92 breast cancer pa- 
tients and of 60 controls have been examined. 
Controls were individuals of both sexes, more 
than 35 years old and known to be unaffected by 
cancer. 
Patients were women with breast cancer admit- 
ted for treatment or already operated upon and 
regularly followed-up at the Gynecologic Oncol- 
ogy Department of the University of Torino. Pa- 
tients median age was 54 years (range 28-78). His- 
topathology was: in situ lobular carcinoma 3, infil- 
trating ductal carcinoma 64, lobular 17, medullary 
4, papillary 1, tubular 3. At the time of diagnosis, 
49 patients were at stage I ,  31 at stage I I , 9  at stage 
III ,3  at stage IV. At the time of blood sampling, al1 
the patients were out of treatment, but 42 had 
received previous adjuvant locoregional radiother- 
apy (5000 cGy) and 32 had received previous cyto- 
toxic chemotherapy (CMF, 18). 
DNA was obtained from peripheral blood leuco- 
cytes by phenol-chloroform extraction. The sam- 
ples were digested with 5 U/pg of AvaII endonu- 
clease according to manufacturer's specifications, 
run on 0.8% agarose gel, and transferred to nitro- 
cellulose membrane by Southern blotting [19]. Pre- 
hybridization (12 hr) and hybridization (18-20 hr) 
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Fig. 2.Southern blotting analysis showing VTR alleles of different length; the number on the top of each lane refers to the rank number 
on Table 1. Lanes 1-10 in gel A and lanes 1-7in gel B contain DNA samples from breast cancer patients; lanes 11-15 in gel A and 8-13 in 
gel B are from norma1 controls. The restriction enzyme used for both gels was Ava 11. The molecular weight markers on the side of each 
gel represent the positions of fragment of known length denved by digesting lambda phage DNA simultaneously with EcoRI and Hind 
111. 
procedures were perforrned at 42°C in a 6 X SSC, 
0.5% SDS, 5 X  Denhart's solution (1% Ficoll, 1% 
PVP, 1% BSA), containing 200pglrnl of salmon 
sperrn DNA and 50% forrnarnide. 
The hybridization probe was a 6.4kb BamHI 
fragment corresponding to the entire Ha-ras gene 
and to 3' flanking sequences including the VTR 
region [20]. The probe was nick-translated to a 
specific activity of l x IO8 cpmlpg. After hybrid- 
ization, the filters were initially washed twice in 2X 
SSC, 0.1% SDS for 20min at room temperature 
and then twice in 0.1 X SSC, 0.1% SDS at 52" C for 
30rnin. The dried filters were subsequently ex- 
posed to X-ray films for various periods of tirne at 
-80" C. 
The allelic VTR fragrnents defining the Ha-ras 
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alleles have been identified by different authors 
[12-161 using different restriction enzymes (Bam- 
HI, MspI, AvaII). As in our hands BamHI gave 
unsatisfactory results in terms of resolution of the 
different bands, according to Thein et al. [13], we 
decided to use AvaII, which produces fragments of 
smaller molecular size and therefore allows a better 
discrimination (Fig. 2). Nevertheless, it was some- 
times difficult to compare the size of the Ha-ras 
alleles between different gels; we then ran gels with 
control DNA samples containing similar sized al- 
leles. However, in our experimental conditions, a 
degree of microheterogeneity of less than 0.05 kb 
cannot be reasonably distinguished, even running 
control DNA samples in adjacent tracks. 
Statistica1 significance of proportion differences 
was calculated by the Chi Square method with 
Yates' correction. Fisher's exact test was used 
when one or more of the expected values was less 
than 5; 95% confidence limits are reported for the 
odds ratio. 
'Common' alleles were defined as those alleles 
whose frequency in norma1 population is above the 
median. For statistica1 analysis, classes with fre- 
quency <0.8 have been pooled with alleles of simi- 
lar size as indicated by small letters in Table 1. 
Results 
Among patients and controls considered together 
(152 cases) we were able to recognize 13 different 
VTR fragments of a molecular size ranging be- 
tween 1.5 and 3.2 kb, and we ranked them from l to 
13. According to the aforementioned criteria we 
defined as 'common' the alleles of 1.50,3.10,2.70, 
and 2.40 kb (Table 2). 
As expected for alleles, no more than two differ- 
ent fragments were observed in a single individua1 
and the absence of fragments was never observed. 
These data suggest the absence of 'blank' alleles 
and justify the direct count of the alleles from the 
RFLP genotypes. 
The distribution of alleles and genotypes found 
in patients and controls are reported in Tables 1 
and 2. The distribution of rare alleles is significant- 
ly different in cases and in controls (p = 0.0002); 34 
rare alleles are found out of 92 breast cancer pa- 
tients and only 4 are found out of 60 controls. The 
most striking result is that alleles with molecular 
size between 1.80 and 2.20 kb are present 31 times 
in patients and only once in controls; this difference 
is highly significant (p<0.0001). 
Considering each single allele, the 2.00 kb allele 
Table I.  Comparison of VTR alleles directly counted from observed RFLP genotypes among breast cancer patients and controls. 
Rank Alleles Patients Controls 
Size (kb) 
n. YO n. % 
Tot. 
" For analysis, classes with expectation <0.8 have been pooled with alleles of similar size as indicated by small letters. 
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(#4), is significantly more frequent in patients 
than in controls (p<0.01), whereas the 2.40 kb al- 
lele (#7), is significantly more frequent in controls 
than in patients (p<0.01). For the other alleles no 
significant distribution differences have been 
found. 
Coming to the comparison of the VTR geno- 
types, the only significant difference is observed for 
the genotype 114 (10192 vs. 1/60; p<0.028). If we 
compare patients and controls bearing at least one 
allele #4 the difference becomes more prominent 
(16176 vs. 1/59; p<0.006). It is therefore appropri- 
ate to calculate the relative risk of developing can- 
cer in carriers of allele # 4 versus al1 other geno- 
types [21]. The odds ratio between patients and 
Table 2. Comparison of the VTR genotypes observed among 
breast cancer patients and controls. 
Geno- Patients Controls 
typesa 
no. 70 NO. ‘?'o 
111 33 35.87 24 40 
112 2 2.17 2 3.33 
113 3 3.26 O - 
114 10 10.87 1 1.67 
(p = 0.03) 
115 4 4.35 O - 
1CI O 3 5.00 
118 O - 1 1.67 
119 1 1.09 1 1.67 
1/10 11 11.96 8 13.33 
1/11 O O l 1.67 
1/12 l1  11.96 13 21.67 
213 1 1.09 O - 
214 1 1.09 O - 
216 1 1.09 O 
2/10 O - 1 1.67 
2/12 2 2.17 1 1.67 
3/13 1 1.09 O - 
414 4 4.35 o - 
411 1 1 1 .O9 O - 
6/10 1 1 .O9 O - 
7/10 O - 1 1.67 
10/10 1 1.09 O - 
10112 4 4.35 3 5.00 
92 100.00 60 100.00 
" The different fragments (alleles) have been indicated with the 
ranks reported in Table 1. Genotypes absent in the two pop- 
ulations have been omitted. 
controls for genotypes containing at least one allele 
#4 is 12.04 (95% confidence limits: 1.65 to 75.1). 
Discussion 
Our data suggest a positive association between an 
increased risk of breast cancer and the presence of 
specific Ha-ras alleles and genotypes. 
The use of different restriction enzymes and the 
small differences in size of the various W R  frag- 
ments make a comparison between the data ob- 
tained by different groups difficult. Our results 
however seem to confirm, on peripheral blood 
DNAs of a large series of breast cancer patients, 
the results obtained by Lidereau et al. [l51 on a 
mixed series of DNAs extracted from leucocytes 
and tumor specimens. 
If subjects carrying specific Ha-ras alleles have a 
higher susceptibility to breast cancer, an inher- 
itable component must be present. This, however, 
may be feeble because of incomplete penetrance 
and need of interaction with other interna1 or envi- 
ronmental factors. In such circumstances, the pres- 
ente of such a component may be difficult to dem- 
onstrate and requires studies on families with large 
genealogic trees. Moreover, a different pattern of 
methylation of the VTR region at the 3' end of the 
Ha-ras proto-oncogene has recently been demon- 
strated for alleles of materna1 or paterna1 origin 
[22] and, as the methylation pattern may influence 
gene expression and therefore the penetrance of 
the different alleles, this may further complicate 
the analysis. 
At present the reasons for differences in the 
VTR sizes to correlate with a higher risk for breast 
cancer is difficult to perceive. In our opinion it is 
hard to conceive that some specific Ha-ras alleles 
should undergo, more easily than others, the rnuta- 
tions that have been described to activate the Ha- 
ras oncogenic potential. It is more likely that other 
unknown differences, within the Ha-ras region and 
in linkage disequilibrium with the VTR polymor- 
phism, may account for an increased risk of dis- 
ease. 
An explanation might originate from recent data 
which suggest a functional role of the VTR region 
152 G Saglio et al. 
itself. Ishii et al. [23] have reported that the VTR's 
act as enhancer elernents on the Ha-ras gene tran- 
scription, and this activity appears to vary accord- 
ing to the VTR length. As already reported, over- 
dosage of the norrnal Ha-ras p21 protein has been 
shown to be able to cause ce11 transforrnation [7]. It 
is therefore conceivable that cells bearing Ha-ras 
alleles allowing a higher leve1 of gene transcription 
could be more susceptible than others to neoplastic 
transforrnation. At present the analysis of the cor- 
relation between the length of the VTRs studied by 
Ishii and co-workers and the naturally existing Ha- 
ras alleles is not possible, but studies are in progress 
to test this hypothesis. 
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